Background Egypt faces many challenges when matching patient needs with available resources. Consequently, there has been an increasing interest in pharmacoeconomics as an aid tool in health decision-making to better allocate resources. Objectives To review and evaluate the volume and the quality of published pharmacoeconomic studies in Egypt. Methods A literature search was conducted in August 2018 using PubMed, Google Scholar, and Cochrane library to identify published Egyptian pharmacoeconomic studies. Articles were included if they were original economic studies, written and published in English, and conducted in Egypt. Each article was assessed independently by two reviewers using the 100-point Quality of Health Evaluation Studies (QHES) scale. Results Fifteen studies published between 2002 and 2017 were included in the review. Most of them were cost-effectiveness analyses (60%). The minority used secondary data (33.3%) or adopted modeling techniques (40%). The mean QHES score of the included studies was 70.1 ± 21.8, and approximately 40% of them had a QHES score of more than 80. Conclusion Pharmacoeconomic evaluations in Egypt are still in their infancy. The Egyptian guidelines for economic evaluation should be adopted and the EQ-5D-5L value sets should be developed to increase the quality of economic research.
Introduction
Egypt is the most populous country in North Africa and the Arab world with an approximate population of 95,000,000 in 2017 [1] . It is classified as a lower middleincome country [2] , where up to 27.8% of the population is living below the poverty line [1] . Since 2011, Egypt has witnessed two revolutions that resulted in dramatic political and economic instabilities [3] . Historically, tourism has been one of the main sources of income and employment in the country, as well as exports and foreign direct investments. These have undergone a severe downturn in recent years, with dramatic implications for economic growth and foreign currency reserves. This has resulted in a huge budget deficit and increasing internal and external debt [3] . Egypt is now facing major financial difficulties that make paying for healthcare services challenging. Compared to other middle-income countries in the region, Egypt's expenditure on health remains low at 6.2% of Gross Domestic Product (GDP). Currently, Government health spending accounts for only 25% of total health expenditure, whereas the regional average is 52%, as per 2009 data [4] . In 2016/2017, the expenditure on health to state budget was only 5% [1] , which does not offer any sort of assistance to citizens with limited incomes.
The Ministry of Health and Population (MoHP) and the Health Insurance Organization (HIO) are the main governmental bodies governing Egypt's healthcare system. The MoHP covers 17% of the population [4] , and the HIO covers 59% of Egyptians [5] . However, only 6% of Egyptians covered by HIO actually utilize its services because the coverage is unsatisfactory. According to the National Health Accounts, in 2008 up to 72% of total health expenditure in Egypt is paid out of pocket (OOP) by people seeking treatment. This high level of OOP is a burden on the Egyptian population, particularly for people in lower income brackets [4] .
Currently, Egypt is working to improve the quality of its public healthcare system. New legislation has been implemented to establish comprehensive insurance cover that is supposed to provide all Egyptians with both insurance and care by 2016. With increasing healthcare costs, inflation and currency devaluation, healthcare needs exceed available resources. In this respect, Egypt is similar to many healthcare systems worldwide. Simply increasing healthcare budget is not an easy fix to narrow the gap between resources available and actual spending, due to the paucity of resources available. Hence, a method to better allocate and utilize existing resources is needed. Pharmacoeconomic studies could play an important role at this crucial time as they evaluate the cost-effectiveness of services (interventions/medications). This information can help the country control resource use and thus reduce the burden on the Egyptian healthcare system. The concepts of pharmacoeconomics were introduced in Western countries in the 1970s. Formal pharmacoeconomics guidelines were first established in Australia and Canada [6, 7] . The significance of pharmacoeconomics studies relies on their ability to translate research findings into healthcare policies. They assist policy-makers in the allocation of scarce healthcare resources [8] and act as a guide to the health sector in implementing effective measures towards a sustainable and highly efficient healthcare system [9] . They also ensure transparency in formulary decision-making in health insurance programs [10] . Pharmacoeconomics and Outcomes Research (PEOR) provides a great tool for decision-making that is based on scientific evidence and real data. Countries that have, or plan to implement, universal healthcare coverage benefit more from PE implementation.
In Egypt, with growing awareness of the importance of pharmacoeconomics and the increasing need for optimizing the use of limited resources, the MoHP established a pharmacoeconomics unit to support and inform pricing and reimbursement decisions. The first recommendations for reporting pharmacoeconomics evaluation were conducted in 2013 [11] . However, there is still a lack of available evidence about the quality of economic studies carried out in Egypt. Poorly designed pharmacoeconomics studies can misguide decision-makers. In order to enhance the decision-making process in Egypt, high quality and well-designed pharmacoeconomic studies are a necessity. A first step in improving study quality is to review and evaluate the current published pharmacoeconomics studies in Egypt.
To the best of our knowledge, no published paper has systematically reviewed pharmacoeconomics studies conducted in Egypt. Thus, the objective of the present study was to investigate the state of pharmacoeconomics research in Egypt by evaluating the volume and quality of published articles in this field.
Methods

Information Sources and Research
A systematic search of the literature was conducted in August 2018 using PubMed, Google Scholar, and the Cochrane library to identify published pharmacoeconomic studies conducted in Egypt. The keywords adopted in the literature review were used alone and in different combinations (see Appendix). Additional relevant articles were identified from the reference lists of the obtained articles. This continued until no more articles could be identified. We limited our search to studies written and published in English and conducted in Egypt. No studies were identified that were written and published in Arabic.
Eligibility Criteria
Included studies had to be original economic studies, including health economic analyses of one or more health-related interventions (drugs, pharmaceuticals, or treatment modalities). Studies were excluded if the cost was not the main topic of the study and if they compared multiple countries. In this review, original evaluations undertaken in Egypt were a requirement for study inclusion. Meeting abstracts, letters to the editor, treatment guidelines or recommendations, expert opinion, and narrative reviews were excluded.
Study Selection
Screening of all identified studies was done independently by two different authors at two different stages. First, titles and abstracts of the articles were reviewed during the primary screening of the initial search results. The reviewers then confirmed which met the inclusion and exclusion criteria. Second, all identified relevant articles obtained during the primary screening were selected for further review of the content of the full text.
Data Collection Process
A data collection form similar to the one developed by Gavaza et al. [12] was used for this study (see Supplementary Material). This form was also adapted from previous published economic guidelines and studies [13] [14] [15] [16] . Moreover, the methodology used for data collection is similar to that used in several previous studies [17] [18] [19] [20] . The data collection form included two sections. First, the general information section included: the total number of authors for the study; country of residence of the lead author; primary training of the lead author; year of publication; journal in which the study was published; the country of the journal in which it was published; type of publication. Second, the economic information section listed: the method of economic evaluation used; the type of costs included; the perspective of the study; the study design; primary outcomes; type of data; disease state investigated; whether economic evaluation was the primary study goal; funding source; type of medical function; the decision reached on whether treatment was cost-effective.
Quality Analysis
Assessment of the full pharmacoeconomics studies (e.g., those studies that compared both costs and outcomes of interventions or conditions) was done using the Quality of Health Evaluation Studies (QHES) scale [15, 21] . The QHES scale is a 16-item tool covering evaluation of study objectives, perspective, economic model, study design, and methodology. Each criterion is weighted depending on its importance in assessing quality (range: 1-9 points for each criterion) and gets either a full score or zero. The QHES scale is a 100-point scale, with lower scores representing poor quality. In our study, a modified version of the QHES scale having three scoring points, full score, a mid-point score (lying midway between zero and the full score for the criterion), or a zero was used [17, 20] . Each article was assessed independently by two blinded reviewers. All disagreements between the reviewers on any of the items in the data collection questionnaire were resolved through discussions and assessment by a third reviewer. If the difference between the scores given by the two reviewers exceeded 10, it was passed to a third reviewer for further evaluation. In this case, the final score of the article was defined as the average score of the third reviewer and a closer score given by either reviewer.
Published articles were grouped by type of evaluation They were considered to be: (i) a cost-minimization analysis (CMA) if costs were compared with evidence of equal effectiveness; (ii) a cost-effectiveness analysis (CEA) if health outcomes were presented in intermediate terms, e.g., disease prevented; (iii) a cost-utility analysis (CUA) if health outcomes were expressed in terms of QALYs or disability-adjusted life-years (DALYs); (iv) a cost-benefit analysis (CBA) if health outcomes were measured in monetary units.
Statistical Analysis
The Statistical Package for the Social Sciences (SPSS) software package version 22 was used for all analyses (SPSS Inc., Chicago, IL, USA). All nominal variables were represented by descriptive statistics as numbers and percentages. The normality pattern of QHES score was explored using the Shapiro-Wilk test of normality. It was found to be normally distributed (P > 0.05) and, hence, parametric tests were adopted. The differences in QHES scale scores by variables (country of residence of the primary author; number of authors; type of publication; costs considered; type of data and study design; whether modeling was adopted or not) were compared using independent sample t tests. Pearson's correlation was used to test correlation between continuous variables. P values less than 0.05 were considered statistically significant.
Results
Study Selection
Fifteen articles were found eligible to be included in this review. Around 2000 studies were identified using search engines by using the keywords mentioned in the methodology section. Figure 1 shows the selection process of the included articles. The abstracts of 83 articles, after the removal of duplications, were examined for their eligibility to the study inclusion and exclusion criteria. Of the considered 83 articles: 14 studies were found to be non-pharmacoeconomics studies; ten articles were not mainly concerned with costs; three studies were comparing more than one country; two studies were not conducted in Egypt; two studies were not original research article studies. In addition, ten more studies were excluded for which full text manuscripts could not be obtained. Forty-two articles were found to be eligible and were considered for further assessment of the full article. Twenty-seven articles were further excluded and only 15 articles met the inclusion and exclusion criteria and were finally included. The included articles were then evaluated using the QHES scale score by two independent reviewers. The difference between the QHES scores of the two reviewers did not exceed 10 in any of the included studies. Thus, the final score was calculated based on the average of both reviewers' score.
Study General Characteristics
In studying the included publications, we found that most of the first authors (66.7%) were residing in Egypt, while 33.3% had a different country of residence. The majority of publications (73.3%) were health economic while only 26.7% were medical publications. It was also noted that the majority of the publishing journals were based in the UK (33.3%) while 20% of the journals were from the USA and 13.3% were Scandinavian. The remaining journals were based in Edinburgh, Egypt, India, the Netherlands, and New Zealand. Corresponding authors were contacted by e-mail to obtain information about the primary training they received. Unfortunately, only two authors responded, therefore these data were not included in our analysis. The general information of the included studies is presented in Table 1 .
Economic Characteristics of the Included Papers
When considering the economic data and analysis of the included studies, the majority (80%) focused on the study of direct costs only, with only three studies (20%) including the indirect costs as well. The majority (60%) had the design of a cost-effectiveness analysis (CEA) while 26.7% were cost-benefit analyses. A minority of the studies carried out cost-utility analysis (20%) and cost-minimization analysis (6.7%). Six (40%) of the included studies adopted modeling in their economic evaluations. In three studies [22] [23] [24] , MARKOV modeling was used. Two other studies utilized the TRIVAC model [25] and a decision model [26] . The remaining study adopted three modeling techniques, which were budget impact analysis, human capital, and generational accounting [27] . Around 33% of the included studies were economic evaluations of prospective cohorts. Of the studies, 26.7% were randomized controlled trials and only one study (6.7%) was a retrospective database. The studied interventions in the included studies were treatment (60%), preventive (40%), or diagnostic (6.7%). Also, the majority of the studies analyzed primary data (67.7%) and stated the funding source (53.3%). The economic data of the included studies are shown in Table 2 .
The first study among those included was conducted in 2002 and the last was in 2017. It is worth noting that the majority of the studies were conducted after 2013 (three articles were published before and 12 articles were published after 2013). Hepatitis C virus was the condition investigated in 33% of the studies owing to the high prevalence of hepatitis C in Egypt and its high medical and economic impact.
Only seven studies gave a perspective for their economic evaluation. These were either societal [22] [23] [24] or governmental perspectives, [25, 28] or both [26, 27] . The outcome measures varied. As expected, costs and the incremental cost-effectiveness ratio (ICER) were used in CEA; costs in CMA; benefit-cost ratio (BCR) in CBA; and, finally, quality-adjusted life-years (QALY), disability-adjusted life-years (DALY), and life-years gained (LYG) in CUA. The majority of the studies proved the treatment/intervention in question to be cost-effective. The outline characteristics of the included studies are shown in Table 3 .
Assessment of Quality of the Included Articles
The mean QHES score of the 15 studies was found to be 70.1 ± 21.8. Forty percent of the studies were of high-quality, with a QHES score of more than 80 out of 100. The lowest average score was 34.25 [29] for the oldest included study, which was conducted in 2002, and the highest was 96, for one of the most recent studies published in 2017 [24] . Although the QHES score was higher in the studies that had first authors residing in countries other than Egypt, this did not reach statistical significance. More than seven authors were found in eight articles (53.3% of included studies). There was no statistical significance in the QHES score between the studies with less than seven authors and those with more than seven authors. Also, QHES scores tended to be higher in medical publications than in medical econodmic publications and in studies that assessed direct costs only, compared with those that assessed both direct and indirect costs. However, none of these factors were statistically significant. Conversely, QHES scores were significantly higher in studies that used secondary data than those with primary data, as well as those that adopted modeling techniques versus those that did not. Also, studies that mentioned a perspective for their economic evaluation tended to have significantly higher QHES scores (P < 0.05, Table 4 ).
Discussion
The present study assessed and evaluated the quantity and quality of pharmacoeconomics studies in Egypt. Based on the study inclusion and exclusion criteria, 15 studies were included. This limited number of included studies is comparable with settings such as Saudi Arabia [30] , Nigeria [18] , Bangladesh [31] , Iran [32] , and Zimbabwe [12] , but lagging behind other developing countries in conducting health-related economic evaluations [17, 20, [33] [34] [35] . Seventy-three percent of the included studies were published after 2013 (Fig. 2) . This is because pharmacoeconomics education in Egypt was in its infancy until 2012 [36] and started to develop in the 3 years after the launch of the Egyptian guidelines for reporting pharmacoeconomic evaluations [11] . Also, the launch of ISPOR's Egypt chapter has helped raise awareness on pharmacoeconomics in Egypt. Through awareness campaigns and educational activities, there is more interest in adopting pharmacoeconomic principles amongst decision-makers in Egypt. Although 66.7% of the primary authors resided in Egypt, 93% of the studies were published in foreign journals. All the studies that carried out modeling (N = 6) had high average QHES score (90.9 ± 6.8), were authored by two or more foreign authors, and were funded internationally. This could be attributed to the lack of data in local hospitals and institutes, as well as a lack of experts in using such modeling techniques. About 60% of the studies were cost-effective analyses, which is comparable to findings in other setting [12, 17, 18, 20, 30-32, 34, 35] . Clinical benefit can be interpreted as naturalistic clinical outcomes, and is more straightforward and the preferred method for economic evaluation. Only three studies carried out CUA as the concept of QALYs is not well understood by the majority of the decision-makers in Egypt, with the absence of an Egyptian tariff for the EQ-5D-5L. Limited studies performed CBA using correct procedures due to the lack of knowledge and experience in using this method to apply a monetary value for human life. Eighty percent of the studies included direct costs only due to the lack of Egyptian data and information on indirect costs [11] .
In this review most of the studies focused on the economic evaluation of infectious disease interventions, which is comparable with lower middle-income countries [37] . In addition, economic evaluation publications for many major health problems in Egypt were absent, indicating a poor distribution of research resources towards the determination of cost-effective interventions. Accordingly, there is more need The average QHES scores given by the two reviewers for PE studies that address non-communicable diseases in Egypt, which also carry a significant disease burden. Although the Egyptian guidelines for reporting pharmacoeconomic evaluations were published in 2013 [11] , only two studies adhered to these guidelines with a high QHES score [28] . Sixty percent of the assessed studies had one or more technical limitations and weaknesses in reporting pharmacoeconomics evaluation such as lack of sensitivity analysis, ICER calculation, and specifying the study perspective. This was in agreement with the economic evaluations conducted in other lower middle-income countries [37] .
Finally, several recommendations to improve pharmacoeconomic evaluations in Egypt should be adopted. First, recommendation of Egyptian guidelines for economic analysis of health technologies should be adopted. This will improve the quality of the pharmacoeconomics studies and make the results more robust. Second, there is a great need to develop a value set for the EQ-5D-5L based on societal preferences in Egypt. This will support the implementation of cost-utility, cost-benefit analysis and health economics modeling by Egyptian academics and researchers to assist decisionmakers in appropriate allocation of healthcare resources. Third, in order to address and to quantify disease burden and to assess the cost-effectiveness of our healthcare interventions, more pharmacoeconomics research/publications are needed in this field. Fourth, pharmacoeconomic capacitybuilding efforts should be continued among relevant stakeholders. Finally, pharmacoeconomics research represents an opportunity for multi-stakeholder collaboration in Egypt as efforts are needed in raising awareness, conducting actual studies, and transitioning towards decision-making that further incorporates pharmacoeconomic studies and principles.
Limitations
Although our research succeeded in its aims, there were some unavoidable limitations. It is probable that some published articles were unintentionally eliminated or missed. Also, our review focused only on studies found during the database search. This may mean that unpublished data like government reports, pharmaceutical company reports, and academic theses were excluded. Additionally, the study may be subjected to publication bias because only published articles were included. There is a greater tendency for studies with positive findings to be published compared to studies with negative outcomes. Finally, the methodology sections of many studies were ambiguous and the authors failed to explain what was carried out explicitly. This may have 
Conclusion
Economic evaluations in Egypt could become a useful source of information for the health system decision-makers. The Egyptian guidelines for economic evaluation should be adopted to increase the quality of economic research in Egypt.
